Moderna, Inc. (MRNA)
| Market Cap | 9.53B |
| Revenue (ttm) | 3.08B |
| Net Income (ttm) | -2.90B |
| Shares Out | 389.08M |
| EPS (ttm) | -7.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,203,220 |
| Open | 24.56 |
| Previous Close | 24.61 |
| Day's Range | 23.91 - 24.77 |
| 52-Week Range | 23.15 - 67.96 |
| Beta | 1.93 |
| Analysts | Hold |
| Price Target | 42.40 (+73.13%) |
| Earnings Date | Nov 6, 2025 |
About MRNA
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MRNA stock is "Hold." The 12-month stock price target is $42.4, which is an increase of 73.13% from the latest price.
News
Pharma tariffs still have a lot of questions outstanding, says Bernstein's Courtney Breen
Courtney Breen, Bernstein senior analyst, joins 'The Exchange' to discuss the companies exempt from pharma tariffs, the country's with existing trade deals and much more.
Moderna, Inc. (MRNA) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Moderna, Inc. (NASDAQ:MRNA) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 25, 2025 10:30 AM EDT Company Participants Rose Loughlin - Executive Vice Pre...
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK
The Moderna Innovation and Technology Centre in Harwell, Oxfordshire is now fully operational and Moderna is licensed to supply British-made COVID-19 vaccines to the UK population The facility marks a...
Moderna: Maintaining Sell Despite Consolidation - And Why MRNY Won't Help Either
Moderna (MRNA) remains a Sell due to weak fundamentals, ongoing cash burn, and lack of meaningful pipeline breakthroughs or financial turnaround. MRNY, the YieldMax MRNA Option Income Strategy ETF, fa...
Moderna says updated next-generation COVID shot shows strong immune response in patients
Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying...
Moderna Announces mNEXSPIKE Generates Strong Immune Response Against LP.8.1 Variant in Humans
Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna's COVID-19 vaccines for the...
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories
CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped to provinces and territories. This milestone ...
Mizuho's Jared Holz: There's not much value left in vaccine stocks
Jared Holz, Mizuho healthcare senior strategist, joins CNBC's 'Squawk on the Street' to discuss outlooks on pharmaceuticals, what new government vaccine panel recommendations mean for the stocks, and ...
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans
Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data...
MRNA Stock vs. PFE & ALNY
On Friday, MRNA stock dropped 7% following a report from The Washington Post that stated a group of health officials reportedly used the Vaccine Adverse Event Reporting System to link the deaths of 25...
Moderna shares hit a low after report suggests the FDA plans to tie COVID shots to child deaths
Pharma stocks took a fresh hit on Friday following a report in The Washington Post that the U.S. Food and Drug Administration reportedly plans to link COVID-19 vaccines with the deaths of 25 minors.
S&P 500 Gains and Losses Today: Warner Bros. and Paramount Extend Gains; Moderna Plunges
Shares of two entertainment giants pushed higher for a second straight day as investors weighed the possibility of a takeover bid, while vaccine makers came under pressure following a report that heal...
Pfizer, Moderna shares plunge on report that Trump officials plan to link 25 child deaths to COVID vaccine
Shares in Pfizer and Moderna fell 3.9% and 7.4%, respectively.
COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says
Shares of companies that make COVID vaccines sank Friday, after a report raised fears that Trump administration health officials will blame the vaccines for some child deaths.
Pfizer, Moderna shares fall on report that Trump officials will link child deaths to Covid shots
Shares of Pfizer and Moderna fell on Friday after a report that Trump administration health officials plan to link Covid vaccines to the deaths of 25 children. The report comes as Health and Human Se...
Trump officials to link child deaths to covid shots, according to reports
CNBC's Angelica Peebles joins 'Money Movers' to discuss Trump officials reported plan to link child deaths to covid shots.
Moderna, Inc. (MRNA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Moderna, Inc. (NASDAQ:MRNA) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Stéphane Bancel - CEO & Director Conference Call Participants T...
Moderna Announces Data to be Presented at the 2025 International Congress of Inborn Errors of Metabolism
CAMBRIDGE, MA / ACCESS Newswire / September 2, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that five abstracts on its investigational mRNA therapeutics have been accepted for presentation at th...
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
mRNA Biotechs - Long-Term Value Risks Abound
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery c...
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2
CAMBRIDGE, MA / ACCESS Newswire / August 27, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applica...
Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone CAMBRIDGE, MA / ACCESS Newswire / August 22, 2025 / Moderna announced today that Health Canada has autho...
Moderna to Present at Upcoming Conferences in September 2025
CAMBRIDGE, MA / ACCESS Newswire / August 21, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced its participation in the following upcoming investor conferences: Morgan Stanley's 23rd Annual Global He...
FDA May Not Renew Pfizer's Authorization For Covid Shots In Younger Children, Moderna Prepares To Boost Supply
Pfizer Inc.'s PFE COVID-19 vaccine for children under five may lose U.S. Food and Drug Administration authorization this fall, raising the possibility of supply shortages and prompting Moderna Inc. MR...